Online inquiry

IVTScrip™ mRNA-Anti-LTB&TNFSF14, BG9924(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3992MR)

This product GTTS-WQ3992MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets LTB&TNFSF14 gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_002341.2; NM_003807.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4050; 8740
UniProt ID Q06643; O43557
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LTB&TNFSF14, BG9924(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ3992MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2370MR IVTScrip™ mRNA-Anti-HGF, AMG 102(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG 102
GTTS-WQ11360MR IVTScrip™ mRNA-Anti-CD19, MEDI-551(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MEDI-551
GTTS-WQ6875MR IVTScrip™ mRNA-Anti-CX3CL1, E-6011(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA E-6011
GTTS-WQ14292MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG-7221(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA RG-7221
GTTS-WQ11963MR IVTScrip™ mRNA-Anti-ERBB3&IGF1R, MM-005(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MM-005
GTTS-WQ5736MR IVTScrip™ mRNA-Anti-CEACAM5, CEA-IL-2v(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CEA-IL-2v
GTTS-WQ15192MR IVTScrip™ mRNA-Anti-TNF, TA-650(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA TA-650
GTTS-WQ14910MR IVTScrip™ mRNA-Anti-stx1B, Shigamabs®(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA Shigamabs®
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW